Figure 1: 1.09Å structure of HIV Protease bound to resistance busting inhibitor
Reiling, Craik, and Stroud Agouron compound in Phase III clinical trials and is effective against multiple drug resistant strains of HIV1.
Figure 2
Unprecedented resolution will lend new insight into catalytic mechanism and substrate binding.